News
-
-
-
COMMUNIQUÉ DE PRESSE
Poster Presentation Describing the Significant Results of Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Breast Cancer Patients to Take Place December 11, 2024 at San Antonio Breast Cancer Symposium (SABCS)
Jaguar Health's Napo Pharmaceuticals to present data on crofelemer in breast cancer patients at SABCS 2024. Additional analyses ongoing. Patient advocacy program also announced -
-
-
COMMUNIQUÉ DE PRESSE
U.S. Investigator-Initiated Trial (IIT) to Evaluate Jaguar Health’s Crofelemer for Short Bowel Syndrome with Intestinal Failure (SBS-IF) Begins
Jaguar Health's crofelemer undergoing clinical studies for rare diseases SBS-IF and MVID in multiple regions; Orphan Drug Designation granted by FDA and EMA -
-
-
COMMUNIQUÉ DE PRESSE
Article about Canalevia-CA1, Jaguar Health's Prescription Drug Conditionally Approved by the FDA for the Treatment of Chemotherapy-Induced Diarrhea in Dogs, Published in PetVet Magazine
Jaguar Health announces Canalevia-CA1, a canine-specific crofelemer drug for chemotherapy-induced diarrhea in dogs with FDA approval, detailed safety information provided -
